{"entity":{"id":"nct06682195","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","aka":["NEOTORCH-BREAST02"],"tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.","summary":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) is a phase 2, interventional study registered as NCT06682195 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 35 participants, started 2024-10-09 and due to reach its primary completion in 2026-10-01. Interventions recorded: Neoadjuvant chemotherapy combined with Toripalimab. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"All patients had triple negative breast cancer confirmed by histopathology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06682195","url":"https://clinicaltrials.gov/study/NCT06682195"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06682195","phase":"2","setting":"Neoadjuvant Chemotherapy Combined With Toripalimab for Triple-negative Breast Cancer : a Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST02)","sponsor":"First Affiliated Hospital of Zhejiang University","participation":[{"nct":"NCT06682195","source":"https://clinicaltrials.gov/study/NCT06682195","fetchedAt":"2026-10-07T16:54:54.827Z","studySha256":"3a1b58813718022dd60ac90ccb485689dd7f03c354d2913a458bda3459e39fd4","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-14","leadSponsor":"First Affiliated Hospital of Zhejiang University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":35,"enrolmentType":"ESTIMATED","siteCount":13,"recruitingSiteCount":8,"countries":["China"]}],"started":"2024-10-09","startedType":"actual","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06682195/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}